Skip to Content
Merck spent much of 2020 developing and testing two COVID-19 vaccine candidates but abandoned the projects in January. The company said in March that it would support the manufacturing and supply of Johnson & Johnson’s COVID-19 vaccine instead. Merck’s worldwide sales increased 2% to $48 billion last year, led by a 30% increase in revenue ($14.4 billion) from its flagship cancer drug Keytruda. Despite the sales growth, Merck saw a 28% decrease in net income in 2020 compared with the prior year. And the numbers in 2021 aren’t exactly flashing green—at least so far: First-quarter sales were flat, and profit declined because of the continuing effects of the pandemic as well as increased competitive pressures for key Merck products. One more challenge for the venerable drugmaker: In June, longtime CEO Ken Frazier steps down after a stellar decade-long run leading the company. He will hand the reins to CFO Robert Davis.
Lists ranking Merck
RANK232
Global 500 - 2021Total revenue for the world’s biggest companies fe...READ MOREview in list
RANK96
100 Best Large Workplaces for Millennials - 2021We surveyed tens of thousands of employees to crea...READ MOREview in list
RANK41
60 Best Large Workplaces in New York - 2021These companies foster supportive cultures, where ...READ MOREview in list
RANK65
Fortune 500 - 2021This year’s Fortune 500 marks the 67th running of ...READ MOREview in list
RANK100
100 Best Companies to Work For - 2021Our 2021 list of the 100 best companies to work fo...READ MOREview in list
RANK9
20 Best Workplaces in Biotechnology and Pharmaceuticals - 2021The best U.S. biotechnology and pharmaceutical com...READ MOREview in list
RANK37*
World’s Most Admired Companies - 2021After a year in which humanity leaned more heavily...READ MOREview in list
RANK53
Change the World - 2020As we face unprecedented collective challenges, co...READ MOREview in list